ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
NCT ID: NCT06745908
Last Updated: 2025-10-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
460 participants
INTERVENTIONAL
2025-10-01
2029-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245
Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer
NCT00362882
Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00118183
Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03358875
Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer
NCT00065182
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental Arm
The treatment regimen for the experimental arm will be as follows. Agents are to be administered in the order listed (eg, on day 1 experimental arm \[cycles 1 and 2\], administer N-803, followed tislelizumab and then followed by docetaxel).
N-803
N-803 1.2 mg SC
Tislelizumab
Tislelizumab 200 mg IV
Docetaxel
Docetaxel 75 mg/m2 IV
Control Arm
The control arm treatment regimen will consist of repeated 3-week cycles with a ± 3-day window for each visit of Docetaxel 75 mg/m2 IV.
Docetaxel
Docetaxel 75 mg/m2 IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
N-803
N-803 1.2 mg SC
Tislelizumab
Tislelizumab 200 mg IV
Docetaxel
Docetaxel 75 mg/m2 IV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age ≥ 18 years old.
2. Able to understand and provide a signed informed consent that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.
3. Pathologically confirmed stage IV NSCLC disease.
4. Have acquired resistance to an immune checkpoint inhibitor, defined as disease progression immediately following an initial response or stable disease (≥ 6 months duration) to exactly 1 line of anti-PD-L1 or anti-CTLA-4 therapy (for Stage III, IV, or recurrent disease) that was given alone or in combination with chemotherapy.
5. Participants with AGA must have 1 or more documented AGA(s): EGFR, ROS1, neurotrophic tyrosine receptor kinase (NTRK), B rapidly accelerated fibrosarcoma (BRAF), mesenchymal epithelial transition (MET) exon 14 skipping, rearranged during transfection (RET), Kirsten RAt sarcoma (KRAS).
6. Participants with AGA must meet the following criteria for advanced or metastatic NSCLC. Participants who have been treated with 1 or 2 prior lines of applicable targeted therapy that is locally approved for the participant's genomic alteration at the time of screening:
1. Participants who have tumors with EGFR L858R or exon 19 deletion mutations must have received prior Osimertinib.
2. Participants who received a targeted agent as adjuvant therapy for early-stage disease must have relapsed or progressed while on the treatment or within 6 months of the last dose or received at least one additional course of targeted therapy for the same genomic alteration (which may or may not be same agent used in the adjuvant setting) for relapsed/progressive disease.
3. Participants who have been treated with a prior tyrosine kinase inhibitor (TKI) must receive additional approved targeted therapy, if locally available and clinically appropriate, for the applicable genomic alteration, or the participant will not be allowed in the study.
7. ECOG performance status of 0 to 2.
8. Measurable tumor lesions according to RECIST v1.1. (at Baseline day 1).
9. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
10. Agreement to practice effective contraception for female participants of child-bearing potential and non-sterile males. Female participants of child-bearing potential must agree to use effective contraception for up to 7 months after completion of therapy, and non-sterile male participants must agree to use a condom for up to 7 months after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), orals, injectables, 2 forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (IUDs), and hormonal therapy.
11. Participants with known HIV infection must be receiving anti-retroviral therapy and have an undetectable viral load at their most recent viral load test within 6 months prior to enrollment.
Exclusion Criteria
1. Systemic autoimmune disease currently requiring treatment (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, or autoimmune disease associated with lymphoma). The participant must have been off treatment for 180 days.
2. History of organ transplant requiring immunosuppression; or history of pneumonitis or interstitial lung disease requiring treatment with systemic steroids; or a history of receiving systemic steroid therapy or any other immunosuppressive medication ≤ 3 days prior to study initiation. Daily steroid replacement therapy (eg, prednisone or hydrocortisone) and corticosteroids used to manage AEs are permitted.
3. Participants with AGA of ALK.
4. History of known active hepatitis B or C infection.
5. Active infection requiring antibiotic therapy.
6. Active treatment with CYP3A4 inhibitors.
7. Received a live vaccine ≤ 4 weeks prior to the first dose of study drug(s).
8. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
9. Participants with known history of severe hypersensitive reactions to docetaxel or to other drugs formulated with polysorbate 80.
10. Had major surgery within 28 days prior to study randomization. Participants must have fully recovered from the effects of prior surgery in the opinion of the treating Investigator.
11. Inadequate organ function, evidenced by the following laboratory results:
1. Absolute lymphocyte count \< institutional upper limit of normal (ULN).
2. Absolute neutrophil count \< 1,500 cells/mm3.
3. Platelet count \< 100,000 cells/mm3.
4. Total bilirubin greater than the ULN; unless the participant has documented Gilbert's syndrome).
5. Aspartate aminotransferase (AST \[serum glutamic-oxaloacetic transaminase; SGOT\]) or alanine aminotransferase (ALT \[serum glutamic pyruvic transaminase; SGPT\]) \> 1.5 × ULN.
6. Alkaline phosphatase (ALP) levels \> 2.5 × ULN.
7. Hemoglobin \< 9.0 g/dL.
8. Serum creatinine \> 2.0 mg/dL or 177 μmol/L or creatinine clearance \< 40 mL/min (using the Cockcroft-Gault formula below):
Female = \[(140 - age in years) × weight in kg × 0.85\] / \[72 × serum creatinine in mg/dL\] Male = \[(140 - age in years) × weight in kg × 1.00\] / \[72 × serum creatinine in mg/dL\]
12. Have any of following:
1. Cirrhosis at a level of Child-Pugh B (or worse);
2. Cirrhosis (any degree) and a history of hepatic encephalopathy; or
3. Clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis.
13. Participation in an investigational drug study or history of receiving any investigational treatment within 21 days prior to study entry, except for hormone-lowering therapy in participants with hormone-sensitive cancer.
14. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
15. Pregnant and nursing women.
16. History of allergic reactions to tislelizumab.
17. History of prior adverse reaction to immunotherapy that led to its permanent discontinuation.
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ImmunityBio, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Highlands Oncology Group
Springdale, Arkansas, United States
Chan Soon-Shiong Institute for Medicine
El Segundo, California, United States
OPN Healthcare INC
Glendale, California, United States
OPN Healthcare INC/ Cancer and Blood Specialty Clinic
Los Alamitos, California, United States
The Oncology Institute of Hope and Innovation
Fort Lauderdale, Florida, United States
Moffit Cancer Center
Tampa, Florida, United States
Emory University - Winship Cancer Institute
Atlanta, Georgia, United States
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
Vanderbilt - Ingram Cancer Center
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ResQ201A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.